重回千亿只是开始?中生BD强势来袭

氨基观察
13 Jun

传统药企,也有惊人的爆发力。年初至今,包括三生制药的传统药企,持续受到资本市场认可。意料之外,但似乎在情理之中。一方面是重大BD直接驱动,另一方面实际上包含了市场对于传统药企的“纠错”。随着BD超预期,创新药不再是biotech的主战场,重燃市场对传统药企的信心和期待,股价表现因此超乎市场想象。它们的估值重塑,看起来并未结束。今日,中国生物制药(01177.HK) 二级市场股价大涨19.29%,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10